Viking Therapeutics Inc. (VKTX)
Where Will Viking Therapeutics Be in 5 Years?
Viking has multiple GLP-1 drugs in development that have been generating impressive results. Given this market's potential, its financials could improve dramatically if one of its drugs is approved.
Is It Too Late to Buy Viking Therapeutics Stock?
Viking Therapeutics stock is up by a significant amount this year. It still has key catalysts on the way that investors should note.
Is Viking Therapeutics Stock a Buy?
Viking's GLP-1 inhibitor candidate has shown promise for weight loss in clinical trials. But investors should keep in mind that the company has no approved products yet.
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. Look at weight loss stocks, like Viking Therapeutics (NASDAQ: VKTX ), for example.
